Literature DB >> 15562021

Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.

G Minniti1, D Traish, S Ashley, A Gonsalves, M Brada.   

Abstract

We assessed the risk of second brain tumors in a cohort of patients with pituitary adenoma treated with conservative surgery and external beam radiotherapy. Four hundred and twenty-six patients (United Kingdom residents) with pituitary adenomas received radiotherapy at the Royal Marsden Hospital (RMH) between 1962 and 1994. They were followed up for 5749 person-years. The cumulative incidence of second intracranial tumors and systemic malignancy was compared with population incidence rates through the Thames Cancer Registry and the National Health Service Central Register (previously OPCS) to record death and the potential causes. Eleven patients developed a second brain tumor, including five meningiomas, four high grade astrocytomas, one meningeal sarcoma, and one primitive neuroectodermal tumor. The cumulative risk of second brain tumors was 2.0% [95% confidence interval (CI), 0.9-4.4%] at 10 yr and 2.4% (95% CI, 1.2-5.0%) at 20 yr, measured from the date of radiotherapy. The relative risk of second brain tumor compared with the incidence in the normal population was 10.5 (95% CI, 4.3-16.7). The relative risk was 7.0 for neuroepithelial and 24.3 for meningeal tumors. The relative risks were 24.2 (95% CI, 4.8-43.5), 2.9 (95% CI, 0-8.5), and 28.6 (95% CI, 0.6-56.6) during the intervals 5-9, 10-19, and more than 20 yr after radiotherapy (four cases occurred >20 yr after treatment). There was no evidence of excess risk of second systemic malignancy. An additional 10-yr update confirmed our previous report of an increased risk of second brain tumors in patients with pituitary adenoma treated with surgery and radiotherapy. The 2.4% risk at 20 yr remains low and should not preclude the use of radiotherapy as an effective treatment option. However, an increased risk of second brain tumors continues beyond 20 and 30 yr after treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15562021     DOI: 10.1210/jc.2004-1152

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  78 in total

1.  Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas.

Authors:  Xiaomin Liu; Hideyuki Kano; Douglas Kondziolka; Kyung-Jae Park; Aditya Iyer; Samuel Shin; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

2.  First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.

Authors:  A Colao; E Martino; P Cappabianca; R Cozzi; M Scanarini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 3.  Radiotherapy and radiosurgery in acromegaly.

Authors:  Frédéric Castinetti; Isabelle Morange; Henry Dufour; Jean Regis; Thierry Brue
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 4.  Stereotactic radiosurgery of benign intracranial tumors.

Authors:  Bruce E Pollock
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 5.  Recurrent non-functioning pituitary adenomas: a review on the new pathological classification, management guidelines and treatment options.

Authors:  P D Delgado-López; J Pi-Barrio; M T Dueñas-Polo; M Pascual-Llorente; M C Gordón-Bolaños
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

Review 6.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Multidisciplinary treatment of giant invasive prolactinomas in paediatric age: long-term follow-up in two children.

Authors:  Mario Francesco Fraioli; Federica Novegno; Elisabetta Catena; Chiara Fraioli; Laura Moschettoni
Journal:  Childs Nerv Syst       Date:  2010-03-30       Impact factor: 1.475

Review 8.  Assessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy.

Authors:  Harald Paganetti
Journal:  Health Phys       Date:  2012-11       Impact factor: 1.316

Review 9.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 10.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.